Notably, its prevalence increases to up to 15% among patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), suggesting that the GFI1-36N variant is implicated in the pathogenesis of MDS and AML [2,3,4]. Here, GFI1 is linked to myelodysplastic syndrome.